Opinions
JoAnne Feeney
BioNTech
BNTX-Q
PAST TOP PICK
Oct 07, 2022
Stock price when the opinion was issued
You might be interested:
Provides the key insight into mRNA that underlies the Covid vaccine. The mRNA technology can be developed into therapies that are targeted and safe. They are working on a flu vaccine as well as a cancer vaccine. Their pipeline is vast and the coronavirus vaccine is giving a huge cash hoard to pay for R&D. (Analysts’ price target is $185.00)
The $28 billion biotech just received FDA approval of their updated COVID vaccine. It trades at 6x earnings, 1.3x book and supports a 23% ROE. We like that cash reserves are growing, while shares are bought back and debt is retired. We recommend placing a stop-loss at $100, looking to achieve $161 -- upside potential of 40%. Yield 0%
(Analysts’ price target is $161.34)This $24 billion German based pharma company has received approvals to continue advancement into a new uterine cancer treatment. It trades at 8x trailing earnings, 1.1x book and supports a 23% ROE. Cash reserves are growing, while stock is bought back. We recommend placing a stop-loss at $78, looking to achieve $137 -- upside potential of 31%. Yield 0%
(Analysts’ price target is $137.07)